NCT06373146 - A Study of Tirzepatide (LY3298176) Plus Mibavademab Compared With Tirzepatide Alone in Adult Participants With Obesity | Biotech Hunter

Enrollment

360

Participants

Timeline

Start Date

April 24, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

April 30, 2026

Conditions

Obesity

Interventions

DRUG

Tirzepatide

Administered SC

DRUG

Mibavademab

Administered SC

DRUG

Tirzepatide-Placebo

Administered SC

DRUG

Mibavademab-Placebo

Administered SC

Trial Locations (17)

45212

CTI Clinical Research Center, Cincinnati

58104

Lillestol Research, Fargo

70072

Tandem Clinical Research, Marrero

70119

Velocity Clinical Research - New Orleans, New Orleans

75230

Velocity Clinical Research, Dallas, Dallas

77040

Juno Research, Houston

78404

South Texas Clinical Research, Corpus Christi

83646

Solaris Clinical Research, Meridian

90017

Velocity Clinical Research, Los Angeles, Los Angeles

90247

Velocity Clinical Research, Gardena, Gardena

91405

Velocity Clinical Research, Panorama City, Van Nuys

91606

Velocity Clinical Research, North Hollywood, North Hollywood

92614

Irvine Clinical Research, Irvine

92704

Velocity Clinical Research, Santa Ana, Santa Ana

94598

Diablo Clinical Research, Inc., Walnut Creek

98007

Northwest Clinical Research Center, Bellevue

08053

Hassman Research Institute Marlton Site, Marlton

All Listed Sponsors

collaborator

Regeneron Pharmaceuticals

INDUSTRY

lead

Eli Lilly and Company

INDUSTRY